CA2253410A1 - New improved formulation for treatment of thromboembolism - Google Patents

New improved formulation for treatment of thromboembolism Download PDF

Info

Publication number
CA2253410A1
CA2253410A1 CA002253410A CA2253410A CA2253410A1 CA 2253410 A1 CA2253410 A1 CA 2253410A1 CA 002253410 A CA002253410 A CA 002253410A CA 2253410 A CA2253410 A CA 2253410A CA 2253410 A1 CA2253410 A1 CA 2253410A1
Authority
CA
Canada
Prior art keywords
pharmaceutical formulation
carbon atoms
absorption enhancing
enhancing agent
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002253410A
Other languages
English (en)
French (fr)
Inventor
Jan-Erik Lofroth
Lennart Lindfors
Anna-Lena Ungell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2253410A1 publication Critical patent/CA2253410A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
CA002253410A 1996-05-31 1997-05-28 New improved formulation for treatment of thromboembolism Abandoned CA2253410A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9602145-6 1996-05-31
SE9602145A SE9602145D0 (sv) 1996-05-31 1996-05-31 New improved formulation for treatment of thromboembolism
PCT/SE1997/000914 WO1997045138A1 (en) 1996-05-31 1997-05-28 New improved formulation for treatment of thromboembolism

Publications (1)

Publication Number Publication Date
CA2253410A1 true CA2253410A1 (en) 1997-12-04

Family

ID=20402816

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002253410A Abandoned CA2253410A1 (en) 1996-05-31 1997-05-28 New improved formulation for treatment of thromboembolism

Country Status (14)

Country Link
US (1) US6673365B1 (de)
EP (1) EP1015022B1 (de)
JP (1) JP2000511526A (de)
AR (1) AR013569A1 (de)
AT (1) ATE284706T1 (de)
AU (1) AU722450B2 (de)
CA (1) CA2253410A1 (de)
DE (1) DE69731981T2 (de)
ID (1) ID19472A (de)
NO (1) NO985558L (de)
NZ (1) NZ332788A (de)
SE (1) SE9602145D0 (de)
WO (1) WO1997045138A1 (de)
ZA (1) ZA974386B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
SE0203349D0 (sv) * 2002-11-12 2002-11-12 Astrazeneca Ab New use
DK1569912T3 (en) 2002-12-03 2015-06-29 Pharmacyclics Inc 2- (2-hydroxybiphenyl-3-yl) -1h-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464175A (en) * 1982-08-25 1984-08-07 Altman Alan R Multipurpose tamponade and thrombosclerotherapy tube
AU1629383A (en) * 1982-10-02 1984-04-05 Amano Seiyaku K.K. Earthworm tissue protease thrombolytic agents
EP0662826A1 (de) * 1992-10-02 1995-07-19 Pfizer Inc. Pharmazeutische zusammensetzungen enthaltend nichtionische tenside
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
SE9302135D0 (sv) * 1993-06-18 1993-06-18 Kabi Pharmacia Ab New pharmaceutical composition
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation

Also Published As

Publication number Publication date
AU722450B2 (en) 2000-08-03
US6673365B1 (en) 2004-01-06
AR013569A1 (es) 2001-01-10
EP1015022B1 (de) 2004-12-15
SE9602145D0 (sv) 1996-05-31
DE69731981D1 (de) 2005-01-20
ID19472A (id) 1998-07-16
NO985558D0 (no) 1998-11-27
DE69731981T2 (de) 2005-12-22
JP2000511526A (ja) 2000-09-05
AU3111597A (en) 1998-01-05
ATE284706T1 (de) 2005-01-15
NO985558L (no) 1998-11-27
EP1015022A1 (de) 2000-07-05
ZA974386B (en) 1997-12-01
WO1997045138A1 (en) 1997-12-04
NZ332788A (en) 2000-05-26

Similar Documents

Publication Publication Date Title
KR100498646B1 (ko) 경구용 펩티드 약학적 조성물
EP0143949B1 (de) Pharmazeutische Zusammensetzung mit Gehalt an Urokinase
JPH09510182A (ja) カプセル封入されたドラッグデリバリー用透明液
CA2446619C (en) Permeation enhancers
PT100400B (pt) Formulacoes de microemulsoes convertiveis
JPS6069028A (ja) インシユリンを含む薬剤組成物
JP2005508938A (ja) プロミセル薬学的組成物
Wright et al. Intra-Articular Therapy in Osteo-Arthritis: Comparison of Hydrocortisone Acetate and Hydro-Cortisone
RU2203649C2 (ru) Новые липосомные векторы активных веществ
Ribet et al. Use of caerulein with submaximal doses of secretin as a test of pancreatic function in man.
EP1015022B1 (de) Neue verbesserte formulierung zur behandlung von thromboembolismus
JPS5910524A (ja) インタ−フエロン組成物およびその製造法
JPH08504759A (ja) 反転性マイクロエマルション組成物
JPH06192107A (ja) グリチルリチン経口剤
PT835097E (pt) Particulas mistas de lipido de bicarbonato coloidal para distribuicao de drogas ou calorias
KR100402037B1 (ko) 베타-갈락토시다제의장용성약제
JPS60215633A (ja) 腸管吸収性ウロキナ−ゼリポソ−ム組成物
JPS6054313A (ja) 腸管吸収性ヘパリン組成物
JPS6233128A (ja) インタ−フエロン腸溶性経口用製剤
Baluda et al. The effects of administration of drugs influencing haemostasis during treatment of patients with burns
JPS6097917A (ja) 腸管吸収性ウロキナ−ゼ組成物
Kiriyama et al. The bioavailability of oral dosage forms of a new HIV‐1 protease inhibitor, KNI‐272, in beagle dogs
JP2002145791A (ja) 抗炎症性組成物
CA1168984A (fr) Medicament a l'action antitumorale
JPH08208464A (ja) 高脂血症の治療及び予防薬

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued